Refractoriness to anti-Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil-Ecuador.

BACKGROUND: Treatment of Helicobacter pylori gastric infection is complex and associated with increased rates of therapeutic failure. This research aimed to characterize the H. pylori infection status, strain resistance to antimicrobial agents, and the predominant lesion pattern in the gastroduodenal mucosa of patients with clinical suspicion of refractoriness to first- and second-line treatment who were diagnosed and treated in a health center in Guayaquil, Ecuador. METHODS: A total of 374 patients with upper gastrointestinal symptoms and H. pylori infection were preselected and prescribed one of three triple therapy regimens for primary infection, as judged by the treating physician. Subsequently, 121 patients who returned to the follow-up visit with persistent symptoms after treatment were studied. RESULTS: All patients had H. pylori infection. Histopathological examination diagnosed chronic active gastritis in 91.7% of cases; premalignant lesions were observed in 15.8%. The three triple therapy schemes applied showed suboptimal efficacy (between 47.6% and 77.2%), with the best performance corresponding to the scheme consisting of a proton pump inhibitor + amoxicillin + levofloxacin. Bacterial strains showed very high phenotypic resistance to all five antimicrobials tested: clarithromycin, 82.9%; metronidazole, 69.7%; amoxicillin and levofloxacin, almost 50%; tetracycline, 38.2%. Concurrent resistance to clarithromycin-amoxicillin was 43.4%, to tetracycline-metronidazole 30.3%, to amoxicillin-levofloxacin 27.6%, and to clarithromycin-metronidazole 59.2%. CONCLUSIONS: In vitro testing revealed resistance to all five antibiotics, indicating that H. pylori exhibited resistance phenotypes to these antibiotics. Consequently, the effectiveness of triple treatments may be compromised, and further studies are needed to assess refractoriness in quadruple and concomitant therapies.

Antibacterial and antifungal activity of curcumin and methylene blue associated with laser on bacterial and fungal strains

Objective:To analyze the effect of methylene blue and 10% curcumin in fungi and bacteria through an in vitrostudy using photodynamic therapy (PDT). Methods:Curcumin and methylene blue were photosensitized by a Photon Lase III laser applied for 90 s in a dark environment within a laminar flow chamber. Enterococcus faecalisand Candida albicans strains were cultured and standardized.Then, a minimum inhibitoryconcentration (MIC) assay was conducted for these photosensitizers, with concentration variations and incubation to evaluate their antimicrobial activity. Results:With PDT, Curcumin had significant antibacterial activity against E. faecalis (MIC = 250 µg/mL).In contrast, methylene blue had antibacterial activity against E. faecalis (MIC < 12.5 µg/mL with PDT) and antifungal activity against C. albicans (MIC <12.5 µg/mL with or without PDT).Both agents showed greater efficacy in the presence of the laser.The results suggest that curcumin and methylene blue associated with laser may effectively treat microbial infections. Conclusion:Further research is needed to evaluate the efficacy and safety of using these agents in animal and human models and theireffectiveness against different bacterial and fungal strains.

Surgical site infections in maxillofacial trauma surgery - Single-dose versus prolonged antibiotic prophylaxis.

Open reduction with internal fixation (ORIF) for facial fractures has frequently been associated with the occurrence of surgical site infections (SSIs). Perioperative antibiotic prophylaxis is customarily recommended for ORIF. Thus, the comparison of two different antibiotic regimens (i.e., single-dose and prolonged antibiotic prophylaxis) concerning the rate and severity of SSIs in facial fracture patients undergoing ORIF was the main purpose of this study. This retrospective analysis included patients who underwent ORIF for facial fractures. They were distributed into two groups. The single-dose antibiotic prophylaxis group (SDAP) received single-dose perioperative antibiotic prophylaxis, whereas the prolonged antibiotic prophylaxis group (PAP) were administered prophylactic antibiosis over a course of 5 days. 122 patients were included in the study. Nine patients in the SDAP group and 15 patients in the PAP group were affected by SSIs; no significant difference in the incidence of SSIs was found (p = 0.218). Moreover, the severity of SSIs did not significantly differ between the two groups (p = 0.982).

Antimicrobial resistance dissemination associated with intensive animal production practices in Argentina: A systematic review and meta-analysis

Resumen El abuso y mal uso de los antimicrobianos aceleró la propagación de bacterias resistentes. La asociación entre las infecciones que presentan resistencia a antimicrobianos (RAM) en humanos y el uso de antimicrobianos en la producción agropecuaria es compleja, pero está bien documentada. Proporcionamos una revisión sistemática y metaanálisis sobre la diseminación de la resistencia a antimicrobianos designados como críticamente importantes por la Organización Mundial de la Salud (OMS) en cerdos, aves y bovinos de producción intensiva y extensiva en Argentina. Se buscó información en bases de datos electrónicas (Medline-PubMed, Web of Science, SciELO, Sistema Nacional de Repositorios Digitales de Argentina) y en la literatura gris. Se incluyeron estudios epidemiológicos sobre la RAM en las principales bacterias transmitidas por los alimentos - Salmonella spp., Campylobacter spp., Escherichia coli y Enterococcus spp. - y bacterias causantes de mastitis aisladas de cerdos, pollos y bovinos. Los resultados de este estudio apoyan la hipótesis de que la RAM de las bacterias transmitidas por los alimentos alcanza niveles alarmantes. Los metaanálisis seguidos de análisis por subgrupos mostraron asociación entre la RAM y (a) el animal (p<0,01) para estreptomicina, ampicilina y tetraciclina o (b) el sistema productivo (p<0,05) para estreptomicina, cefotaxima, ampicilina, ácido nalidíxico y tetraciclina. La mayor prevalencia conjunta de multirresistencia se detectó en cerdos (0,47 [0,29; 0,66]) y producción intensiva (0,62 [0,34; 0,83]), mientras que la menor correspondió a bovinos de leche (0,056 [0,003; 0,524]) y producción extensiva (0,107 [0,043; 0,240]). Se observó un vacío de información respecto de los bovinos de feedlot. Es urgente adoptar medidas políticas para coordinar y armonizar la vigilancia de la RAM y regular el uso de antimicrobianos en animales.

Abstract Abuse and misuse of antimicrobial agents has accelerated the spread of antimicrobial-resistant bacteria. The association between antimicrobial-resistant infections in humans and antimicrobial use in agriculture is complex, but well-documented. This study provides a systematic review and meta-analysis of the dissemination of antimicrobial resistance (AMR) to antimicrobials defined as critically important by the WHO, in swine, chicken, and cattle from intensive and extensive production systems in Argentina. We conducted searches in electronic databases (MEDLINE-PubMed, Web of Science, SciELO, the National System of Digital Repositories from Argentina) as well as in the gray literature. Inclusion criteria were epidemiological studies on AMR in the main food-transmitted bacteria, Salmonella spp., Campylobacter spp., Escherichia coli and Enterococcus spp., and mastitis-causing bacteria, isolated from swine, chicken, dairy and beef cattle from Argentina. This study gives evidence for supporting the hypothesis that AMR of common food-transmitted bacteria in Argentina is reaching alarming levels. Meta-analyses followed by subgroup analyses confirmed the association between the prevalence of AMR and (a) animal species (p<0.01) for streptomycin, ampicillin and tetracycline or (b) the animal production system (p<0.05) for streptomycin, cefotaxime, nalidixic acid, ampicillin and tetracycline. Moreover, swine (0.47 [0.29; 0.66]) and intensive production (0.62 [0.34; 0.83]) showed the highest pooled prevalence of multidrug resistance while dairy (0.056 [0.003; 0.524]) and extensive production (0.107 [0.043; 0.240]) showed the lowest. A research gap regarding beef-cattle from feedlot was identified. Finally, there is an urgent need for political measures meant to coordinate and harmonize AMR surveillance and regulate antimicrobial use in animal production.

Drug-Resistant Tuberculosis and COVID-19: A Scoping Review on a New Threat to Antimicrobial Resistance / Tuberculosis Resistente a Medicamentos y COVID-19: Una Revisión de Alcance de una Nueva Amenaza a la Resistencia Antimicrobiana / Tuberculose droga-resistente e COVID-19: revisão de escopo de uma nova ameaça à resistência microbiana a medicamentos

ABSTRACT Objective: To assess the impact of COVID-19 on the morbidity and mortality associated with drug-resistant tuberculosis (DR-TB). Methods: A comprehensive review of articles published in international databases since December 2019 was conducted. The findings are presented in a narrative format, supplemented with tables, diagrams, and a map created using ArcGIS software. Results: Thirty-five studies were selected, highlighting the significant consequences of COVID-19 on TB and DR-TB treatment progress. Four main thematic areas were identified: Clinical and epidemiological aspects of the interaction between COVID-19 and DR-TB; Management of physical resources and the team; Challenges and circumstances; Perspectives and possibilities. Conclusions: This study revealed that the COVID-19 pandemic significantly negatively impacted the control of long-standing diseases like TB, particularly in the context of morbidity and mortality related to DR-TB.

RESUMEN Objetivo: Evaluar el impacto de COVID-19 en la morbilidad y mortalidad asociada con la tuberculosis resistente a medicamentos (DR-TB). Métodos: Se realizó una revisión integral de artículos publicados en bases de datos internacionales desde diciembre de 2019. Los hallazgos se presentaron de forma narrativa, complementados con tablas, diagramas y un mapa creado con el software ArcGIS. Resultados: Se seleccionaron 35 estudios que destacaron las consecuencias significativas de COVID-19 en el progreso del tratamiento de la TB y la DR-TB. Se identificaron cuatro áreas temáticas principales: "Aspectos clínicos y epidemiológicos de la interacción entre COVID-19 y DR-TB", "Gestión de recursos físicos y del equipo", "Desafíos y circunstancias" y "Perspectivas y posibilidades". Conclusiones: Este estudio reveló que la pandemia de COVID-19 tuvo un impacto negativo significativo en el progreso del control de enfermedades antiguas como la TB, especialmente en el contexto de la morbilidad y mortalidad relacionada con la DR-TB.

RESUMO Objetivo: Avaliar o impacto da COVID-19 na morbimortalidade associada à tuberculose resistente a medicamentos (DR-TB). Métodos: Realizou-se uma revisão abrangente de artigos publicados em bases de dados internacionais a partir de dezembro de 2019. As evidências foram apresentadas de maneira narrativa, com o suporte de tabelas, diagramas e um mapa elaborado no software ArcGIS. Resultados: Foram selecionados 35 estudos que destacaram as consequências significativas da COVID-19 nos avanços no tratamento da TB e da DR-TB. Quatro áreas temáticas foram identificadas: "Aspectos clínicos e epidemiológicos da interação entre COVID-19 e DR-TB", "Gestão de recursos físicos e da equipe", "Desafios e circunstâncias" e "Perspectivas e potencialidades". Conclusões: Este estudo evidenciou que a pandemia de COVID-19 teve um impacto negativo significativo na progressão do controle de uma doença ancestral como a TB, especialmente no contexto da morbimortalidade por DR-TB.

Evolución histórica de la Organización Mundial de la Salud y la resistencia a los antimicrobianos / Historical evolution of World Health Organization guidelines on antimicrobial resistance / Evolução histórica da Organização Mundial da Saúde e a resistência aos antimicrobianos

RESUMEN Objetivo. Mostrar la evolución de los lineamientos sobre políticas públicas en salud enfocadas en farmacorresistencia microbiana o resistencia a los antimicrobianos (RAM) que la Organización Mundial de la Salud (OMS) ha emitido desde 1948 hasta 2022. Además, se mencionan otras acciones gubernamentales relacionadas. Métodos. Se llevó a cabo una revisión detallada de los archivos de la Asamblea Mundial de la Salud y el Consejo Ejecutivo de la OMS. Se realizó un análisis textual de resoluciones sobre la RAM, que dan pauta al diseño de políticas y acciones gubernamentales para los Estados Miembros de la OMS. También se realizó una búsqueda sistemática en SCOPUS, Pubmed y literatura gris con categoría de análisis: políticas públicas en salud sobre la RAM. Resultados. La RAM se ha convertido en la mayor amenaza para la salud pública, y compromete el cumplimiento de los objetivos de desarrollo sostenible. Presentamos resoluciones de la OMS como evidencia de lineamientos para combatir la RAM. En consonancia, se menciona el enfoque "Una salud", estrategias, iniciativas, planes y programas relacionados. Se identificó una brecha en la investigación y el desarrollo de antimicrobianos nuevos, que requiere un análisis más profundo. Conclusiones. La OMS ha realizado esfuerzos para combatir la RAM. Esto ha generado un desarrollo integral de políticas públicas en salud, para que los Estados Miembros las apliquen según la soberanía de sus gobiernos.

ABSTRACT Objective. Show the evolution of guidelines on public health policies focused on antimicrobial resistance (AMR) issued by the World Health Organization (WHO) between 1948 and 2022. Other related government actions are also mentioned. Methods. A detailed review was conducted of World Health Assembly and WHO Executive Board archives. A textual analysis was conducted of AMR-related resolutions that guide the design of government policies and actions for WHO Member States. A systematic search was carried out in SCOPUS, PubMed, and grey literature under the category of public health policies on AMR. Results. AMR has become the greatest threat to public health, putting at risk the achievement of the Sustainable Development Goals. WHO resolutions are presented as evidence of guidelines to combat AMR. The One Health approach and related strategies, initiatives, plans, and programs are mentioned. A gap was identified in the research and development of new antimicrobials, requiring further analysis. Conclusions. WHO has made efforts to combat AMR. This has generated comprehensive development of public health policies to be implemented by the governments of Member States as they see fit.

RESUMO Objetivo. Apresentar a evolução das diretrizes sobre políticas públicas de saúde voltadas para a resistência microbiana a medicamentos ou resistência aos antimicrobianos (RAM) publicadas pela Organização Mundial da Saúde (OMS) de 1948 a 2022. Além disso, mencionam-se outras ações governamentais relacionadas. Métodos. Procedeu-se a uma revisão detalhada dos arquivos da Assembleia Mundial da Saúde e do Conselho Executivo da OMS. Realizou-se uma análise textual das resoluções sobre RAM, que orientam a formulação de políticas e ações governamentais para os Estados Membros da OMS. Fez-se também uma busca sistemática nas plataformas SCOPUS e Pubmed e na literatura cinzenta, com a categoria de análise "políticas públicas de saúde sobre RAM". Resultados. A RAM tornou-se a maior ameaça à saúde pública e prejudica o cumprimento dos Objetivos de Desenvolvimento Sustentável. Apresentamos as resoluções da OMS como evidência de diretrizes para combater a RAM. Nesses termos, mencionam-se a abordagem "Saúde Única" e estratégias, iniciativas, planos e programas relacionados. Identificou-se uma lacuna na pesquisa e no desenvolvimento de novos antimicrobianos, o que requer uma análise mais aprofundada. Conclusões. A OMS envidou esforços para combater a RAM, o que levou ao desenvolvimento integral de políticas públicas de saúde a serem aplicadas pelos Estados Membros, em conformidade com a soberania de seus governos.

Frecuencia del gen mecA en Staphylococcus aureus meticilinorresistente en un hospital de tercer nivel en Perú

Objetivos: determinar la frecuencia del gen mecA en Staphylococcus aureus resistente a meticilina (MRSA) aislados de pacientes atendidos en un hospital de tercer nivel en la región Cajamarca, Perú; asimismo, determinar cuál de los dos antibióticos usados como screening fenotípico tiene mayor utilidad para explicar la presencia de dicho gen. Métodos: se analizaron 71 aislamientos bacterianos provenientes de muestras del Hospital Regional Docente de Cajamarca, la identificación de S. aureus se llevó a cabo mediante el equipo MicroScan. El screening fenotípico para resistencia a meticilina se realizó mediante la técnica de difusión, con discos de cefoxitina y oxacilina. La extracción de ADN se realizó mediante shock térmico, la detección del gen mecA se realizó mediante reacción en cadena de la polimerasa. El análisis estadístico se realizó con el software SPSS v.25. Resultados: de los 71 aislados, 40 (56,3%) fueron MRSA portadores del gen mecA, la mayoría de estos aislamientos correspondieron a pacientes hospitalizados 22 (31,0%), siendo más frecuentes en muestras de secreción bronquial 27 (38,0%). El screening fenotípico con disco de cefoxitina predijo mejor la presencia del gen mecA [P=0,010; Exp(B)= 12,3] en comparación con el disco de oxacilina. Conclusiones: este estudio demostró alta frecuencia de MRSA mecA positivo en muestras de origen clínico, principalmente de pacientes hospitalizados. Es importante establecer medidas de vigilancia para identificar MRSA en todos los hospitales de la región.

Objective: to determine the frequency of the mecA gene in methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients treated at a third-level hospital in the Cajamarca region, Peru; as well as, to determine which of the two antibiotics used as phenotypic screening is more useful in explaining the presence of said gene. Methods: 71 bacterial isolates were analyzed from samples obtained from the Hospital Regional Docente of Cajamarca. The identification of S. aureus was carried out using the MicroScan system. Phenotypic screening for resistance to methicillin was performed using the diffusion technique with cefoxitin and oxacillin discs. DNA extraction was performed by heat shock, mecA gene detection was performed through polymerase chain reaction. For data analysis, the statistical software SPSS v.25 was used. Results: from 71 isolates, 40 (56,3%) were MRSA carriers of the mecA gene, the majority of these isolates corresponded to hospitalized patients 22 (31,0%), being more frequent in bronchial secretion samples 27 (38,0%). Phenotypic screening with cefoxitin disc was a better predictor for the presence of the mecA gene [P=0,010; Exp(B)= 12,3] compared to the oxacillin disc. Conclusions: It is shown a high frequency of positive MRSA mecA in samples of clinical origin, mainly from hospitalized patients. It is important to establish surveillance guidelines to identify MRSA in all hospitals in the region.

Anti-Tuberculosis Activity of Three Carbapenems, Clofazimine and Nitazoxanide Using a Novel Ex Vivo Phenotypic Drug Susceptibility Model of Human Tuberculosis.

We evaluated a novel physiological 3-D bioelectrospray model of the tuberculosis (TB) granuloma to test the activity of a known anti-TB drug, clofazimine; three carbapenems with potential activity, including one currently used in therapy; and nitazoxanide, an anti-parasitic compound with possible TB activity (all chosen as conventional drug susceptibility was problematical). PBMCs collected from healthy donors were isolated and infected with M. tuberculosis H37Rv lux (i.e., luciferase). Microspheres were generated with the infected cells; the anti-microbial compounds were added and bacterial luminescence was monitored for at least 21 days. Clavulanate was added to each carbapenem to inhibit beta-lactamases. M. tuberculosis (MTB) killing efficacy was dose dependent. Clofazimine was the most effective drug inhibiting MTB growth at 2 mg/L with good killing activity at both concentrations tested. It was the only drug that killed bacteria at the lowest concentration tested. Carbapenems showed modest initial activity that was lost at around day 10 of incubation and clavulanate did not increase killing activity. Of the carbapenems tested, tebipenem was the most efficient in killing MTB, albeit at a high concentration. Nitazoxanide was effective only at concentrations not achievable with current dosing (although this might partly have been an artefact related to extensive protein binding).

Helicobacter pylori: novedades, genes de virulencia y resistencia a los antibióticos en Colombia / Helicobacter pylori: novelties, virulence genes and antibiotic resistance in Colombia / Helicobacter pylori: novidades, genes de virulência e resistência aos antibióticos na Colômbia

Helicobacter pylori es un carcinógeno tipo I resistente a múltiples antibióticos y con alta prioridad en salud pública. La infección por este microorganismo está influenciada por una interacción compleja entre la genética del huésped, el entorno y múltiples factores de virulencia de la cepa infectante. Afecta al 50 % de la población mundial, provocando afecciones gastroduodenales graves, la mayoría de forma asintomática. El 20 % de los individuos con H. pylori pueden desarrollar a través del tiempo lesiones gástricas preneoplásicas y el 2 % de ellos un cáncer gástrico. Las manifestaciones clínicas gastrointestinales y extragastrointestinales están asociadas a su virulencia y a la respuesta del sistema inmunológico con la liberación de citosinas proinflamatorias, tales como TNF-alfa, IL-6, IL-10 e IL-8, causantes de inflamación aguda y crónica. Múltiples factores de virulencia han sido estudiados como el gen A asociado a la citotoxina (CagA) y la citotoxina vacuolante (VacA), los cuales juegan un rol importante en la aparición del cáncer gástrico. Dada la resistencia cada vez mayor a los antibióticos utilizados, las líneas de estudio en el futuro inmediato deben estar encaminadas en establecer la utilidad de los nuevos antibióticos y la determinación de profagos colombianos en todo el país. Esta revisión tiene como objetivo hacer una puesta al día sobre las características del H. pylori, los mecanismos patogénicos, genes de virulencia, su asociación con el mayor riesgo de cáncer gástrico, farmacorresistencia microbiana y su erradicación.

Helicobacter pylori is recognized as a class I carcinogen resistant to multiple antibiotics and with high priority in public health. The infection caused by this microorganism is influenced by a complex interaction between host genetics, environment, and multiple virulence factors of the infecting strain. It affects 50% of the world population, causing severe gastroduodenal conditions, most of them asymptomatic. Through time, 20% of individuals with H. pylori may develop preneoplastic gastric lesions and 2% of them develop gastric cancer. The gastrointestinal and extra-gastrointestinal clinical manifestations are associated with its virulence and the response of the immune system with the release of pro-inflammatory cytokines, such as TNF-alpha, IL-6, IL-10 and IL-8, which cause acute and chronic inflammation. Multiple virulence factors have been studied, such as cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA), which play an important role in the development of gastric cancer. Due to the increasing antibiotics resistance, the research in the immediate future should be aimed at establishing the usefulness of the new antibiotics and the determination of Colombian prophages throughout the country. This paper aims to update the characteristics of H. pylori, its pathogenic mechanisms, virulence genes, its association with the increased risk of gastric cancer, microbial drug resistance, and eradication.

Helicobacter pylorié um carcinógeno tipo I resistente a múltiplos antibióticos e com alta prioridade na saúde pública. A infecção por este microrganismo está influenciada por uma interação complexa entre a genética do hospede, o entorno e múltiplos fatores de virulência da cepa infectante. Afeta a 50% da população mundial, provocando afeções gastroduodenais graves, a maioria de forma assintomática. 20% dos indivíduos com H. pylori podem desenvolver através do tempo lesões gástricas pré-neoplásicas e 2% deles um câncer gástrico. As manifestações clínicas gastrointestinais e extragastrointestinais estão associadas à sua virulência e à resposta do sistema imunológico com a liberação de citocinas pró-inflamatórias, tais como TNF-alfa, IL-6, IL-10 e IL-8, causantes de inflamação aguda e crónica. Múltiplos fatores de virulência hão sido estudados como o gene. A associado à citotoxina (CagA) e a citotoxina vacuolante (VacA), os quais jogam um papel importante no aparecimento do câncer gástrico. Dada a resistência cada vez maior aos antibióticos utilizados, as linhas de estudo no futuro imediato devem estar encaminhadas em estabelecer a utilidade dos novos antibióticos e a determinaçãode profagos colombianos em todo o país. Esta revisão tem como objetivo fazer uma atualização sobre as características do H. pylori, os mecanismos patogénicos, genes de virulência, sua associação com o maior risco de câncer gástrico, farmacorresistência microbiana e sua erradicação.

Microbiological analysis of patients with first and recurrent episodes of acute cholangitis in a middle-sized hospital: A single-center retrospective study in rural North Kyoto, Japan.

BACKGROUND: Knowledge of the bacterial spectrum involved in acute cholangitis is essential for adequate empiric antibiotic treatment. There is a lack of published data comparative data between patients with first and recurrent episodes of acute cholangitis. This study aimed to analyze the microbial spectrum in patients with first and second episodes of acute cholangitis. METHODS: We retrospectively assessed 251 patients with first episodes of acute cholangitis between January 2014 to September 2020. RESULTS: At the first episode of acute cholangitis, the predominant strains belonged to Escherichia coli (17.9%), followed by Klebsiella spp. (15.5%), Enterobacter spp. (6.4%), and Enterococcus spp. (5.6%). During follow-up, acute cholangitis recurred in 109 patients; at the second episode, the predominant strains belonged to Enterococcus spp. (35.8%), followed by Klebsiella spp. (27.5%), Enterobacter spp. (22.9%), and Escherichia coli (15.6%). Enterococcus spp. were the most common pathogen in patients with second episode of acute cholangitis, regardless of whether the cholangitis was caused by a malignant tumor or a benign disease. CONCLUSIONS: Unlike in patients with a first episode of acute cholangitis, clinicians should consider empirical treatment with anti-enterococcal antibiotics in patients with recurrent episodes of acute cholangitis.

Resistencia antimicrobiana en Escherichia coli aislada de urocultivos / Antimicrobial resistance in Escherichia coli isolated from urine cultures / Resistência antimicrobiana em Escherichia coli isolada de culturas de urina

Las infecciones del tracto urinario (ITU) son un problema de salud común, la morbilidad por infecciones del tracto urinario adquiridas en la comunidad es alta y el uropatógeno más frecuente en este estudio es Escherichia coli. OBJETIVO. Determinar la resistencia de antimicrobianos en E. coli aislada de urocultivos, durante Enero - Julio 2019, en pacientes que asistieron al laboratorio clínico Neolab. MATERIALES Y METODOS. La investigación es de tipo cuantitativa, documental, de corte longitudinal descriptiva. Se desarrolló en la ciudad de Cuenca, con un universo de 936 pacientes atendidos en el laboratorio clínico Neolab de Enero a Julio de 2019 con un muestreo no probabilístico por conveniencia con lo cual se obtuvo una muestra de 330 registros de datos, cuyos urocultivos presentaron E. coli. RESULTADOS. Se observó resistencia del 55,15% en Amoxicilina, Ácido Nalidíxico 50,91 % y Trimetoprim Sulfametoxazol 46,67%, Ciprofloxacino 26,67%, se evidencia mayor resistencia en mujeres tanto en ß-lactámicos, Quinolonas, Sulfas y Macrólidos, se encontró que el mayor número de pacientes se encuentran dentro del grupo de adultos que representa el 54,4 % y adulto mayor con 25,3%. CONCLUSIONES. La resistencia elevada a los antibióticos estudiados, podrían sugerir un uso empírico de los mismos, la detección de estas cifras representa una señal de alarma. La automedicación facilitada por la venta libre de antimicrobianos empeora el problema, por lo que se requiere control estricto y legislación oportuna.

Urinary tract infections (UTI) are a common health problem, morbidity from community-acquired urinary tract infections is high, and the most common uropathogen in this study is Escherichia coli. OBJECTIVE. To determine the antimicrobial resistance in E. coli isolated from urine cultures, during January - July 2019, in patients who attended the Neolab clinical laboratory. MATERIALS AND METHODS. The research is quantitative, documentary, descriptive longitudinal cut. It was developed in the city of Cuenca, with a universe of 936 patients treated in the Neolab clinical laboratory from January to July 2019 with a non-probabilistic convenience sampling with which a sample of 330 data records was obtained, whose urine cultures presented E coli. RESULTS. Resistance of 55.15% was observed in Amoxicillin, Nalidixic Acid 50.91% and Trimethoprim Sulfamethoxazole 46.67%, Ciprofloxacin 26.67%, greater resistance is evidenced in women both in ß-lactams, Quinolones, Sulfas and Macrolides It was found that the largest number of patients are within the group of adults that represents 54.4% and the elderly with 25.3%. COCLUSIONS. The high resistance to the studied antibiotics could suggest an empirical use of them, the detection of these figures represents an alarm signal. Self-medication facilitated by the over-the-counter sale of antimicrobials worsens the problem, requiring strict control and timely legislation.

As infecções do trato urinário (IU) são um problema de saúde comum, a morbidade das infecções do trato urinário adquiridas na comunidade é alta e o uropógeno mais frequente neste estudo é a Escherichia coli. OBJETIVO. Para determinar a resistência antimicrobiana em E. coli isolada de culturas de urina, durante janeiro - julho de 2019, em pacientes que freqüentam o laboratório clínico Neolab. MATERIALS E MÈTODOS. Esta é uma pesquisa longitudinal quantitativa, documental e descritiva. Foi desenvolvido na cidade de Cuenca, com um universo de 936 pacientes atendidos no laboratório clínico do Neolab de janeiro a julho de 2019 com uma amostragem não-probabilística por conveniência, com a qual foi obtida uma amostra de 330 registros de dados, cujas culturas de urina apresentaram E. coli. RESULTADOS. Foi observada uma resistência de 55,15% em Amoxicilina, Ácido Nalidíxico 50,91% e Trimethoprim Sulfametoxazol 46,67%, Ciprofloxacina 26,67%, maior resistência é evidenciada nas mulheres tanto em ß-lactams, Quinolones, Sulfas e Macrolides, verificou-se que o maior número de pacientes está dentro do grupo adulto representando 54,4% e adulto mais velho com 25,3%. CONCLUSÕES. A alta resistência aos antibióticos estudados poderia sugerir um uso empírico de antibióticos, e a detecção destes números representa um sinal de alarme. A automedicação facilitada pela venda sem prescrição de antimicrobianos agrava o problema, de modo que é necessário um controle rigoroso e legislação oportuna.

Patrones de resistencia en agentes bacterianos involucrados en otitis caninas en Medellín, Colombia, durante 2019: análisis retrospectivo / Patterns of resistance in bacterial agents involved in canine otitis at Medellín, Colombia, during 2019: retrospective analysis

RESUMEN Dentro de los agentes patógenos en los procesos otíticos bacterianos, se destacan microorganismos como Staphylococcus pseudintermedius, Pseudomona auriginosa, Proteus mirabi-lis, Escherichia coli, Corynebacterium spp., Enterococcus spp. y Streptococcus spp., para los cuales se ha descrito resistencia frente a los antibióticos empleados para combatirlos. En Colombia son pocos los reportes acerca de la resistencia antibiótica de microorganismos causantes de otitis. Por ello, el objetivo de esta investigación fue determinar los agentes bacterianos más frecuentemente aislados en infecciones otíticas de caninos remitidas a un laboratorio veterinario de Medellín durante el 2019 y su resistencia a antibióticos. Para llevarlo a cabo, se realizó un estudio descriptivo transversal retrospectivo. Se analizaron los resultados de los antibiogramas realizados a partir de cultivos bacterianos en muestras óticas remitidas a un laboratorio de referencia de la ciudad de Medellín. Además, se efectuó un análisis de frecuencias para la muestra total. Se encontró que los principales microorganismos bacterianos aislados fueron Staphylococcus pseudintermedius, Pseudomona auriginosa, Proteus mirabili y Staphylococcus aureus. La gentamicina fue el medicamento que mayor porcentaje de resistencia presentó y la cefalexina el que menos resistencia presentó. Se pudo concluir que el Staphylococcus pseudintermedius está presente en más del 60% de los casos de otitis bacteriana. Adicionalmente, se observó una variación de la resistencia presentada por los microorganismos en el tiempo. Estos presentaron mayor resistencia ante los antibióticos aminoglucósidos.

ABSTRACT Among the pathogens in bacterial otic processes, microorganisms such as Staphylococcus pseudintermedius, Pseudomona auriginosa, Proteus mirabilis, Escherichia coli, Corynebac-terium spp., Enterococcus spp., and Streptococcus spp. stand out, for which resistance to antibiotics has been described employed to combat them. In Colombia there are few reports about the antibiotic resistance of microorganisms that cause otitis. For that reason, the purpose of this study was to determine the bacterial agents most frequently isolated from canine ear infections and their resistance to antibiotics from samples of ear secretions sent to a veterinary laboratory in Medellín during 2019. In order to do that, an cross-sectional, retrospective descriptive study was done. The results of the antibiograms performed from bacterial cultures obtained from ear samples sent to a reference laboratory in the city of Medellín were analyzed. A frequency analysis was carried out for the total sample. It was found that the main isolated bacterial microorganisms were Staphylococcus pseudintermedius, Pseudomona auriginosa, Proteus mirabili and Staphylococcus aureus. Gentamicin was the drug with the highest percentage of resistance and cephalexin the one with the least resistance. It was possible to conclude that Staphylococcus pseudintermedius is linked in more than 60% of cases of bacterial otitis and the resistance presented by microorganisms varies over time. The group of aminoglycosides antibiotics was the one which microorganisms are manifesting more percentage of resistance.

Sequence type 17 is a predictor of subsequent bacteremia in vancomycin-resistant Enterococcus faecium-colonized patients: a retrospective cohort study.

BACKGROUND: Sequence type (ST) 17 vancomycin-resistant Enterococcus faecium (VREF) is frequently isolated in nosocomial settings. The aim of this study was to identify whether ST17 contributes to subsequent bacteremia more often than other STs among hospitalized patients carrying VREF. METHODS: A retrospective cohort study was conducted in patients carrying ST17 VREF and those with non-ST17 VREF. Rectal screening according to hospital policy was used to identify patients with VREF. Subsequent VREF bacteremia events within a year of detection of colonization were recorded. Cox regression analysis was used to adjust the covariates involved in determining the association between ST17 and subsequent bacteremia events. RESULTS: The cohorts comprised 52 patients with ST17 and 169 patients with non-ST17 VREF. One-year VREF bacteremia-free rates were 85.9% and 90.2%, respectively. In multivariate analysis, ST17 was associated with subsequent bacteremia at an adjusted hazard risk (aHR) of 4.02 (95% confidence interval [CI], 1.32-12.29). Liver transplantation (aHR, 40.08; 95% CI, 4.87-329.76) and hematologic malignancy (aHR, 20.97; 95% CI, 4.87-87.82) were also significant. All cases of subsequent bacteremia in ST17 VREF carriers were caused by ST17; however, subsequent bacteremia in non-ST17 carriers was often caused by ST17 or another ST variant. CONCLUSIONS: A specific genotype, ST17 is a predictor of subsequent bacteremia in hospitalized patients carrying VREF. Patients with a hematologic malignancy and those receiving a liver transplant are also at high risk. More targeted strategies may be needed to prevent VREF infection in hospitals.

Resistencia antimicrobiana en infección del tracto urinario con bacteriuria en el servicio de urgencia de un hospital comunitario de la región de Ñuble, Chile

RESUMEN Introducción: la infección del tracto urinario es entre las enfermedades infecciosas una de gran incidencia en el adulto y la segunda con mayor incidencia en niños. Su tratamiento es inicialmente empírico y se sustenta fundamentalmente en la epidemiología y susceptibilidad local. Objetivos: identificar los microorganismos causales, la resistencia a antimicrobianos y el tratamiento prescrito empíricamente a pacientes consultantes por infecciones del tracto urinario con bacteriuria asociada en la unidad de emergencia del Hospital Comunitario de Bulnes, Chile, entre enero y junio del 2019. Metodología: se realizó un estudio descriptivo retrospectivo. Los datos fueron obtenidos desde los registros del Hospital comunitario de Bulnes, Chile, utilizando el código CIE-10: N39.0, de donde se obtuvo el resultado de los exámenes, datos clínicos, y el perfil biodemográfico de la muestra utilizando un instrumento construido por los autores. Resultados: el microorganismo aislado con mayor frecuencia fue Escherichia coli, en esta bacteria el mayor porcentaje de resistencia se asocia a ampicilina y ciprofloxacino. Los antibióticos utilizados para el tratamiento empírico de estas infecciones fueron principalmente cefadroxilo y ciprofloxacino. El inicio del tratamiento en su mayoría fue sin resultado de urocultivo y sin cambios posteriores al resultado. Conclusiones: en el hospital comunitario de la región de Ñuble, la infección urinaria presentó una alta incidencia en mujeres, con un cuadro clínico caracterizado por disuria, no siendo excluyente para otra sintomatología. La bacteria preponderante fue E. coli, que mostró un alto porcentaje de resistencia a 1 o más antimicrobianos, siendo la ampicilina y el ciprofloxacino los antibióticos con mayor frecuencia en este sentido. No se logró evidenciar errores en la continuidad en el manejo clínico.

ABSTRACT Introduction: Urinary tract infection is one of the infectious diseases with a high incidence in adults and the second with the highest incidence in children. Its treatment is initially empirical and is fundamentally based on epidemiology and local susceptibility. Objectives: To identify the causative microorganisms, antimicrobial resistance and the empirically prescribed treatment to patients consulting for urinary tract infections with associated bacteriuria in the emergency unit of the Community Hospital of Bulnes, Chile, between January and June 2019. Methodology: A retrospective descriptive study was carried out. The data were obtained from the records of the Community Hospital of Bulnes, Chile, using the ICD-10 code: N39.0, from which the results of the examinations, clinical data, and the biodemographic profile of the sample were obtained using an instrument constructed by the authors. Results: The most frequently isolated microorganism was Escherichia coli, in this bacterium the highest percentage of resistance is associated with ampicillin and ciprofloxacin. The antibiotics used for the empirical treatment of these infections were mainly cefadroxil and ciprofloxacin. The start of treatment was mostly without urine culture results and without changes after the result. Conclusions: In the Community Hospital of the Ñuble region, urinary infection had a high incidence in women, with a clinical picture characterized by dysuria, not excluding other symptoms. The preponderant bacterium was E. coli, which showed a high percentage of resistance to one or more antimicrobials, and ampicillin and ciprofloxacin were the most frequent antibiotics in this regard. It was not possible to show errors in continuity in the clinical management.

Estratégias para o uso seguro de antimicrobianos pela enfermagem no ambiente hospitalar: revisão integrativa / Strategies for the safe use of antimicrobials by nursing in the hospital environment: an integrative review / Estrategias para el uso seguro de antimicrobianos por parte de la enfermería en el ámbito hospitalario: revisión integradora

OBJETIVO: identificar as estratégias para o uso seguro de antimicrobianos adotadas pela enfermagem no ambiente hospitalar. MÉTODO: revisão integrativa, realizada no período de junho a julho de 2020, nas bases de dados da LILACS, MEDLINE, CINAHL e EMBASE. Selecionaram-se artigos de 2015 a junho de 2020. Para a análise dos níveis de evidência, adotou-se o método Grading of Recomendations Assessment, Developing and Evaluation. RESULTADOS: encontraram-se oito artigos, distribuídos em estratégias gerenciais e assistenciais de enfermagem, relacionadas ao uso seguro de antimicrobianos. DISCUSSÃO: dentre as principais estratégias gerenciais, destacam-se o papel de educador do enfermeiro e a formação de comitês de monitoramento multidisciplinar; e dentre as assistenciais, as especificidades técnicas da administração de antimicrobianos. CONCLUSÃO: as principais estratégias práticas de Enfermagem encontradas foram educação profissional no uso racional e monitoramento multidisciplinar na resistência antimicrobiana no ambiente hospitalar. Acredita-se que a identificação dessas estratégias contribua para o desenvolvimento de melhores práticas na segurança medicamentosa.

OBJECTIVE: to identify the strategies for the safe use of antimicrobials adopted by Nursing in the hospital environment. METHOD: an integrative review, carried out from June to July 2020, on the LILACS, MEDLINE, CINAHL, and EMBASE databases. Articles from 2015 to June 2020 were selected. For the analysis of the evidence levels, the Grading of Recommendations Assessment, Development and Evaluation was adopted. RESULTS: eight articles were found, distributed in Nursing management and care strategies, related to the safe use of antimicrobials. DISCUSSION: among the main managerial strategies, the role of the educator and the setting up of multidisciplinary monitoring committees stand out; and, among the care strategies, the technical specificities of antimicrobial stewardship. CONCLUSION: the main Nursing practical strategies found were professional education in the rational use and multidisciplinary monitoring of antimicrobial resistance in the hospital environment. It is believed that the identification of these strategies will contribute to the development of better practices in drug safety.

OBJETIVO: identificar las estrategias para el uso seguro de antimicrobianos adoptadas por la enfermería en el ámbito hospitalario. MÉTODO: revisión integradora, realizada de junio a julio de 2020, de las bases de datos de LILACS, MEDLINE, CINAHL y EMBASE. Se seleccionaron artículos de 2015 a junio de 2020. Para el análisis de niveles de evidencia se adoptó el método Grading of Recomendations Assessment, Developing and Evaluation. RESULTADOS: se encontraron ocho artículos, distribuidos en estrategias gerenciales y asistenciales de enfermería, relacionados con el uso seguro de antimicrobianos. DISCUSIÓN: entre las principales estrategias gerenciales se destaca el rol de la enfermera educadora y la conformación de comités de seguimiento multidisciplinarios; y entre las asistenciales, las especificidades técnicas de la administración de antimicrobianos. CONCLUSIÓN: las principales estrategias prácticas de enfermería encontradas fueron la formación profesional en el uso racional y el seguimiento multidisciplinario de la resistencia a los antimicrobianos en el ámbito hospitalario. Se cree que la identificación de estas estrategias contribuye al desarrollo de mejores prácticas en seguridad de medicamentos.

Fosfomicina en el tratamiento de la infección urinaria baja en niños mayores de 6 años. Evolución clínico-microbiológica / Fosfomycin for low urinary-tract infections in children of over 6 years of age. Clínical-microbiological evolution / Fosfomicina no tratamento da infecção do trato urinário baixo em crianças maiores de 6 anos de idade. Evolução clínico-microbiológica

Resumen: Introducción: fosfomicina trometamol (FT) representa una alternativa al tratamiento de la infección del tracto urinario (ITU) baja. Uruguay no dispone de información acerca de su uso en niños. Objetivo: describir la evolución clínica y microbiológica de una cohorte de niños mayores de 6 años con ITU baja tratados con FT. Material y método: se incluyeron niños mayores de 6 años con ITU baja de dos prestadores de salud de Montevideo, entre 1/2/2018 - 30/6/2019. A todos se indicó FT 2 g monodosis y urocultivo de control. Se realizó seguimiento telefónico. Se evaluó: clínica, antecedentes de ITU, microorganismo, susceptibilidad antimicrobiana y evolución: tiempo de resolución clínica, resolución microbiológica, efectos adversos, recurrencia en los primeros tres meses. Resultados: se incluyeron 46 niños, mediana de edad 9,4 años, antecedentes de ITU 13. Presentaron disuria 44, tenesmo 33, polaquiuria 31. Microorganismo aislado: E. coli 43, S. saprophyticus 2, Proteus sp 1. Todos susceptibles a FT, excepto S. saprophyticus naturalmente resistente. Resolución clínica en 48 horas: 42. Se obtuvo urocultivo de control en 31/46 niños: resolución microbiológica 22, no resolución 5 y contaminado 4. Presentaron efectos adversos 9: vómitos 1, diarrea 8 y cefalea 1. Seguimiento telefónico a 40/46 pacientes: reinfecciones al mes de tratamiento: 6. Conclusiones: no se registró resistencia adquirida en los microorganismos. Se observó resolución clínica en las primeras 48 horas en la mayoría de los casos. Los efectos adversos fueron leves. Ocurrieron reinfecciones en una proporción pequeña. Los resultados avalan a FT como alternativa terapéutica para ITU baja en mayores de 6 años.

Summary: Introduction: fosfomycin tromethamine (FT) is an alternative to the treatment of low urinary tract infection (UTI). Uruguay does not have information about its use in children. Objective: to describe the clinical and microbiological evolution of a cohort of children older than 6 years of age with low UTI treated with FT. Materials and methods: we included children of over 6 years of age with low UTI from two health providers in Montevideo between 2/1/2018 and 6/30/2019. We prescribed a single dose of FT 2 g and a control urine culture to all patients. We carried out a telephone follow-up and assessed their clinical record, history of UTI, microorganisms, antimicrobial susceptibility and evolution: time of clinical resolution, microbiological resolution, adverse effects, and recurrence during the first 3 months. Results: 46 children were included, median age 9.4 years, history of UTI 13. 44 presented dysuria, 33 tenesmus, 31 pollakiuria. Isolated microorganism: E. coli 43, S. saprophyticus 2, Proteus sp 1. All susceptible to FT, except S. saprophyticus, naturally resistant. Clinical resolution in 48 hours: 42. Control urine culture was obtained in 31/46 children: microbiological resolution 22, no resolution 5 and contaminated 4. Adverse effects 9: vomiting 1, diarrhea 8, and headache 1. Telephone follow-up carried out for 40 / 46 patients: reinfections after one month of treatment: 6. Conclusions: microorganisms had not acquired resistance. Most cases showed clinical resolution during the first 48 hours. Adverse effects were mild. Reinfections occurred in a small proportion. The results support FT as a therapeutic alternative for low UTI for the case of children of over 6 years of age.

Resumo: Introdução: A fosfomicina trometamina (FT) é uma alternativa ao tratamento da infecção do trato urinário baixo (ITU). O Uruguai não possui informações sobre seu uso em crianças. Objetivo: Descrever a evolução clínica e microbiológica de uma coorte de crianças maiores de 6 anos de idade com ITU baixa tratada com TF. Materiais e métodos: Foram incluídas crianças maiores de 6 anos de com ITU baixa de dois provedores de saúde em Montevidéu; no período 1/2 / 2018 e 30/06/2019. Todos os pacientes receberam indicação de FT 2 g em dose única, cultura de urina e controle. Realizou-se um rastreamento por telefone. Se avaliou: prontuário clínico, história de ITU, microrganismos, suscetibilidade a antimicrobianos e evolução: tempo de resolução clínica, resolução microbiológica, efeitos adversos, recorrência nos primeiros 3 meses. Resultados: Incluíram-se 46 crianças, mediana de idade 9,4 anos, história de ITU 13. 44 delas apresentaram disúria, tenesmo 33, polaciúria 31. Microrgoanismo isolado: E. coli 43, S. saprophyticus 2, Proteus sp 1. Todas suscetíveis a FT, exceto S. saprophyticus, naturalmente resistente. Resolução clínica em 48 horas: 42. Obtivemos cultura de urina controle em 31/46 crianças: resolução microbiológica 22, sem resolução 5 e contaminada 4. 9 delas apresentaram efeitos adversos 9: vômito 1, diarreia 8 e dor de cabeça 1. Realizamos acompanhamento telefônico em 40 / 46 pacientes: reinfecções um mês após tratamento, 6. Conclusões: Os microrganismos não adquiriram resistência. Na maioria dos casos observou-se resolução clínica nas primeiras 48 horas. Os efeitos adversos foram leves. As reinfecções ocorreram em pequena proporção. Os resultados apoiam o TF como uma alternativa terapêutica para ITU baixa para casos de crianças maiores de 6 anos de idade.

Una aproximación a la tuberculosis resistente a isoniazida: ¿un problema subestimado en Colombia? / An appraisal of the isoniazid resistant tuberculosis in Colombia: a underestimated problem in Colombia?

Objetivo: Describir las características clínicas y desenlaces al tratamiento de los pacientes con tuberculosis resistente a isoniazida (Hr-TB) en una institución del suroccidente colombiano. Materiales y métodos: Se realizó un estudio observacional retrospectivo. Se incluyeron pacientes con confirmación diagnóstica, aislamiento microbiológico, pruebas de susceptibilidad a fármacos y evidencia de Hr-TB. Resultados: Se incluyeron 32 pacientes con Hr-TB entre 2006-2018 que corresponden al 6% (32/528) de resistencia del total de casos. El 78% (n=25) fueron casos nuevos, resistencia primaria, y el 22% (n=7) previamente tratados, resistencia adquirida. La comorbilidad más frecuente fue infección por VIH (n=9). El patrón de Hr-TB mostró en 23 (72%) casos con alto nivel, 4 (12%) de bajo nivel y 5 (16%) con bajo y alto nivel. El análisis de resultados al tratamiento se realizó a 22 pacientes, presentando el 50% cura, el 41% tratamiento completo y 9% muerte relacionada con la tuberculosis. Conclusiones: La Hr-TB predomina en los casos nuevos, lo que supone un obstáculo al tratamiento donde no se realizan las pruebas de susceptibilidad de forma rutinaria.

Objective: To describe the clinical characteristics and outcomes to the treatment of patients with isoniazid-resistant tuberculosis (Hr-TB) in an institution in southwest Colombia. Materials and methods: A retrospective observational study was conducted. Patients with diagnostic confirmation, microbiological isolation, drug susceptibility tests, and evidence of Hr-TB were included. Results: Thirty-two patients with Hr-TB were included between 2006-2018, corresponding to 6% (32/528) of resistance in total cases. 78% were new cases, primary resistance, and 22% previously treated, acquired resistance. The most frequent comorbidity was HIV infection (n = 9). The pattern of Hr-TB showed in 23 (72%) cases with high level, 4 (12%) of low level and 5 (16%) with low and high level. The analysis of treatment results was performed on 22 patients, presenting 50% cure, 41% completed treatment, and 9% death related to tuberculosis. Conclusions: Hr-TB predominates in new cases, which is an obstacle to treatment where susceptibility tests are not performed routinely.

Microbiological characteristics of infections in a group of colombian patients with oncological diagnosis, 2014 - 2016 / Características microbiológicas de infecciones en un grupo de colombianos con diagnóstico oncológico, 2014 - 2016

Objective: We aimed to describe the microbiological characteristics of infections in patients from an oncological center during 2.014-2.016. Methods: In this cross-sectional descriptive study, a total of 7.837 cultures corresponding to 1.216 patients were included. Microbiological and sociodemographic data were taken from cancer diagnosed patients admitted to Oncólogos de Occidente S.A. in Pereira, Armenia, Manizales and Cartago from January 2.014 to December 2.016. The bacterial resistance profiles were defined according to the CLSI guideline. Culture foci were blood, urine, tissue biopsies, skin and soft tissues, mucous membranes and feces. Results: The culture-positive rate was 27,94%. Amongst 2.190 isolates, Escherichia coli (22,42%) was the most frequent, followed by Klebsiella pneumonia (21,27%), Pseudomona aeruginosa (13,83%) and Staphylococcus aureus (5,11%). The most common mechanisms of antimicrobial resistance in Gram-negatives were Extended-Spectrum β-Lactamase (45,45%) and AmpC-type β-lactamases (37,71%). Discussion: Up to nearly one-third of our participants' cultures were positive and a vast majority were gram-negatives, provided with ESBLs or AmpCs which in oncological patients it is a catastrophic outcome. We recommend to establish antibiotic dispensing policies thus achieving a microbiological risk control and improve the epidemiological surveillance. Empirical use of beta-lactams with extended spectrum or cephalosporins of 1 to 3 generation is not recommended due to the high resistance found.

Objetivo: Describir las características microbiológicas de las infecciones en pacientes de un centro oncológico durante 2.014-2.016 Métodos: Estudio descriptivo, transversal. Incluyó 7.837 cultivos de 1.216 pacientes. Se recolectaron variables microbiológicas y sociodemográficas de pacientes diagnosticados con cáncer en las sedes de Pereira, Armenia, Manizales y Cartago de Oncólogos de Occidente S.A. durante 2.014 hasta 2.016. Los perfiles de resistencia bacteriana se definieron de acuerdo con la guía CLSI. Los focos de cultivo fueron sangre, orina, biopsias de tejidos, piel y tejidos blandos, membranas mucosas y heces. Resultados: La tasa de cultivo positivo fue del 27,94%. De 2.190 aislamientos, E. coli (22,42%) fue el más frecuente, seguido de K. pneumoniae (21,27%), P. aeruginosa (13,83%) y S. aureus (5,11%). Los principales mecanismos de resistencia identificados en Gram negativos fueron β-lactamasas de espectro extendido (45,45%) y β-lactamasa de tipo AmpC (37,71%). Discusión: Cerca de un tercio de los cultivos de los participantes fueron positivos y una vasta mayoría fueron gram negativos, provistos con ESBL o AmpC, lo que en pacientes oncológicos es un desenlace catastrófico. Recomendamos establecer políticas de dispensación de antibióticos, logrando así un control de riesgo microbiológico y mejorar la vigilancia epidemiológica. No se recomienda el uso empírico de betalactámicos con espectro extendido o cefalosporinas de 1 a 3 generación debido a la alta tasa de resistencia encontrada.

Uso de antibióticos en el hospital general del Departamento de San Pedro - Paraguay

RESUMEN Introducción: Los antibióticos han constituido la herramienta más eficaz para la lucha contra enfermedades infecciosas y trasmisibles. Sin embargo, en los últimos tiempos su efectividad se ha visto afectada por la resistencia antimicrobiana, que a su vez es determinada en gran medida por el uso apropiado o inapropiado de antibióticos. Objetivo: Determinar la frecuencia puntual de uso de antibióticos en el Hospital General del Departamento de San Pedro Paraguay - Corea en el 2019. Metodología: Estudio observacional, descriptivo sobre el uso de antibióticos. Se incluyeron pacientes hospitalizados del 26 al 29 de agosto 2019. Se evaluó el motivo de indicación, clase de antibiótico y cumplimiento de guías terapéuticas. Los datos fueron cargados y analizados en la plataforma RedCap. Resultados: Fueron incluidos 62 pacientes. El 53,23 % de los pacientes fueron del sexo femenino, de 21 a 27 años en un 19,35 %. La frecuencia puntual de uso de antibióticos fue del 91,94 %, de los cuales 38,60 % fue para una profilaxis y 61,40 % para uso terapéutico. El diagnóstico más frecuente fue neumonía (31,43%) y el prescriptor más frecuente fue el médico responsable (85,48%). Entre los casos terapéuticos, se observó que el 94,29 % fue de uso empírico. Las familias de antibióticos empleados con mayor frecuencia fueron: cefalosporina de primera y tercera generación 25,64 %. Se observó un 52,63 % de uso no adecuado de antibióticos. Conclusión: Se ha destacado la elevada frecuencia de uso de antimicrobianos y una importante proporción de uso inadecuado en el Hospital General Paraguay-Korea. Es importante establecer los programas de optimización de uso de antimicrobianos y fortalecer los comités de infecciones asociadas al cuidado de la salud.

ABSTRACT Introduction: Antibiotics have been the most effective tool for the fight against infectious and communicable diseases. However, in recent times its effectiveness has been affected by antimicrobial resistance, which in turn is largely determined by the appropriate or inappropriate use of antibiotics. Objective: To determine the specific frequency of antibiotic use in the General Hospital of the Department of San Pedro Paraguay - Korea in 2019. Methodology: An observational, descriptive study on the use of antibiotics was done. Patients hospitalized from August 26 to 29, 2019 were included. The reason for indication, class of antibiotic and compliance with therapeutic guidelines were evaluated. The data was uploaded and analyzed on the RedCap platform. Results: A total of 62 patients were included. Of this patients 53.23% were female, aged 21 to 27 years (19.35%). The specific frequency of antibiotic use was 91.94%, of which 38.60% was for prophylaxis and 61.40% for therapeutic use. The most frequent diagnosis was pneumonia (31.43%) and the most frequent prescriber was the responsible physician (85.48%). Among the therapeutic cases, it was observed that 94.29% were for empirical use. The most frequently used antibiotic families were: first and third generation cephalosporin 25.64%. A 52.63% of inappropriate use of antibiotics was observed. Conclusion: The high frequency of antimicrobial use and a significant proportion of inappropriate use in the Paraguay-Korea General Hospital have been highlighted. It is important to establish antimicrobial use optimization programs and strengthen health care-associated infection committees.

Evaluación de la calidad microbiológica de productos naturales procesados de uso medicinal comercializados en Quito, Ecuador / Evaluation of the microbiological quality of natural processed products for medicinal use marketed in Quito, Ecuador

RESUMEN Objetivos: Determinar la calidad microbiológica de una muestra de productos naturales procesados de uso medicinal de libre comercio en Quito, Ecuador. Materiales y métodos: 83 productos se sometieron a recuentos de microorganismos aerobios, mohos y levaduras por técnicas convencionales estandarizadas, de acuerdo a la Farmacopea de los Estados Unidos (USP, por sus siglas en inglés). Se identificaron los microorganismos presentes y se determinó su sensibilidad antimicrobiana usando el método de difusión en agar. Resultados: El 17,0% de los jarabes, el 27,0% de los productos tópicos y el 43,0% de los sólidos orales excedieron los límites especificados para el recuento total de microorganismos aerobios, mientras que el 33,0% de los jarabes, el 7,0% de los productos tópicos y el 36,0% de los sólidos orales excedieron el límite para mohos y levaduras. Los productos de uso ocular no pasaron la prueba de esterilidad. El género bacteriano más frecuentemente aislado fue Bacillus, seguido por Escherichia coli, Klebsiella y Enterobacter. Salmonella ni Staphylococcus aureus se encontraron en ningún producto, pero microorganismos potencialmente patógenos como Pseudomonas se aislaron en el 40,0% de los colirios. Enterobacter y Escherichia coli mostraron resistencia a múltiples compuestos y Pseudomonas no fue resistente a ningún antibiótico. Conclusiones: La calidad microbiológica de los productos examinados no fue adecuada. Se aislaron microorganismos potencialmente patógenos y resistentes a antibióticos. Estos productos podrían no ser aptos para su distribución y consumo, aun cuando muchos de ellos cuenten con registro sanitario. El control y regulación por los entes responsables es indispensable.

ABSTRACT Objectives: To determine the microbiological quality of samples from processed natural products used for medicinal purposes and marketed in Quito, Ecuador. Materials and methods: Aerobic microorganisms, molds and yeasts were counted by conventional standardized techniques, according to the United States Pharmacopoeia (USP), in samples from 83 products. The microorganisms found were identified and their antimicrobial sensitivity was determined using the agar diffusion method. Results: The total aerobic microorganism count exceeded the specified limits in 17.0% of syrups, 27.0% of topical products and 43.0% of oral solids; the molds and yeasts count exceeded the limit in 33.0% of syrups, 7.0% of topical products and 36.0% of oral solids. Products for eye use did not pass the sterility test. The most frequently isolated bacterial genus was Bacillus, followed by Escherichia coli, Klebsiella and Enterobacter. Salmonella and Staphylococcus aureus were not found in any product, but potentially pathogenic microorganisms such as Pseudomonas were isolated in 40.0% of the eye drops. Enterobacter and Escherichia coli showed resistance to multiple compounds and Pseudomonas was not resistant to any antibiotic. Conclusions: The microbiological quality of the products examined was not adequate. Potentially pathogenic and antibiotic resistant microorganisms were isolated from the samples. These products may not be suitable for distribution and consumption, even though many of them have sanitary registration. Control and regulation by the corresponding authorities is essential.